Corrigendum to ‘No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial’ [European Neuropsychopharmacology 53 (2021) 34–46, (S0924977X21003746), (10.1016/j.euroneuro.2021.07.092)]

Bernhard T. Baune; Emma Sampson; Jennie Louise; Hikaru Hori; K. Oliver Schubert; Scott R. Clark; Natalie T. Mills; Célia Fourrier

doi:10.1016/j.euroneuro.2022.09.005

Corrigendum to ‘No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial’ [European Neuropsychopharmacology 53 (2021) 34–46, (S0924977X21003746), (10.1016/j.euroneuro.2021.07.092)]

Bernhard T. Baune
, Emma Sampson
, Jennie Louise
, Hikaru Hori
, K. Oliver Schubert
, Scott R. Clark
, Natalie T. Mills
, Célia Fourrier

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The authors regret that the upper IQR values reported in Table 1 for the baseline age and hsCRP were wrong for the Vortioxetine + Placebo group and for the Vortioxetine + Celecoxib group. Table 1 has been updated with the correct values. The authors would like to apologise for any inconvenience caused.

Original language	English
Pages (from-to)	61-62
Number of pages	2
Journal	European Neuropsychopharmacology
Volume	64
DOIs	https://doi.org/10.1016/j.euroneuro.2022.09.005
Publication status	Published or Issued - Nov 2022
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Neurology
Clinical Neurology
Psychiatry and Mental health
Biological Psychiatry
Pharmacology (medical)

Access to Document

10.1016/j.euroneuro.2022.09.005

Cite this

Baune, B. T., Sampson, E., Louise, J., Hori, H., Schubert, K. O., Clark, S. R., Mills, N. T., & Fourrier, C. (2022). Corrigendum to ‘No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial’ [European Neuropsychopharmacology 53 (2021) 34–46, (S0924977X21003746), (10.1016/j.euroneuro.2021.07.092)]. European Neuropsychopharmacology, 64, 61-62. https://doi.org/10.1016/j.euroneuro.2022.09.005

Baune, Bernhard T. ; Sampson, Emma ; Louise, Jennie et al. / Corrigendum to ‘No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression : A 6-week double-blind placebo controlled randomized trial’ [European Neuropsychopharmacology 53 (2021) 34–46, (S0924977X21003746), (10.1016/j.euroneuro.2021.07.092)]. In: European Neuropsychopharmacology. 2022 ; Vol. 64. pp. 61-62.

@article{08cad21a4bf7405f9f7741104e7f8c76,

title = "Corrigendum to {\textquoteleft}No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial{\textquoteright} [European Neuropsychopharmacology 53 (2021) 34–46, (S0924977X21003746), (10.1016/j.euroneuro.2021.07.092)]",

abstract = "The authors regret that the upper IQR values reported in Table 1 for the baseline age and hsCRP were wrong for the Vortioxetine + Placebo group and for the Vortioxetine + Celecoxib group. Table 1 has been updated with the correct values. The authors would like to apologise for any inconvenience caused.",

author = "Baune, \{Bernhard T.\} and Emma Sampson and Jennie Louise and Hikaru Hori and Schubert, \{K. Oliver\} and Clark, \{Scott R.\} and Mills, \{Natalie T.\} and C{\'e}lia Fourrier",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier B.V. and European College of Neuropsychopharmacology",

year = "2022",

month = nov,

doi = "10.1016/j.euroneuro.2022.09.005",

language = "English",

volume = "64",

pages = "61--62",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier BV",

}

Baune, BT, Sampson, E, Louise, J, Hori, H, Schubert, KO, Clark, SR, Mills, NT & Fourrier, C 2022, 'Corrigendum to ‘No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial’ [European Neuropsychopharmacology 53 (2021) 34–46, (S0924977X21003746), (10.1016/j.euroneuro.2021.07.092)]', European Neuropsychopharmacology, vol. 64, pp. 61-62. https://doi.org/10.1016/j.euroneuro.2022.09.005

Corrigendum to ‘No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial’ [European Neuropsychopharmacology 53 (2021) 34–46, (S0924977X21003746), (10.1016/j.euroneuro.2021.07.092)]. / Baune, Bernhard T.; Sampson, Emma; Louise, Jennie et al.
In: European Neuropsychopharmacology, Vol. 64, 11.2022, p. 61-62.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Corrigendum to ‘No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression

T2 - A 6-week double-blind placebo controlled randomized trial’ [European Neuropsychopharmacology 53 (2021) 34–46, (S0924977X21003746), (10.1016/j.euroneuro.2021.07.092)]

AU - Baune, Bernhard T.

AU - Sampson, Emma

AU - Louise, Jennie

AU - Hori, Hikaru

AU - Schubert, K. Oliver

AU - Clark, Scott R.

AU - Mills, Natalie T.

AU - Fourrier, Célia

PY - 2022/11

Y1 - 2022/11

N2 - The authors regret that the upper IQR values reported in Table 1 for the baseline age and hsCRP were wrong for the Vortioxetine + Placebo group and for the Vortioxetine + Celecoxib group. Table 1 has been updated with the correct values. The authors would like to apologise for any inconvenience caused.

AB - The authors regret that the upper IQR values reported in Table 1 for the baseline age and hsCRP were wrong for the Vortioxetine + Placebo group and for the Vortioxetine + Celecoxib group. Table 1 has been updated with the correct values. The authors would like to apologise for any inconvenience caused.

UR - https://www.scopus.com/pages/publications/85139060752

U2 - 10.1016/j.euroneuro.2022.09.005

DO - 10.1016/j.euroneuro.2022.09.005

M3 - Comment/debate

AN - SCOPUS:85139060752

SN - 0924-977X

VL - 64

SP - 61

EP - 62

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

ER -

Baune BT, Sampson E, Louise J, Hori H, Schubert KO, Clark SR et al. Corrigendum to ‘No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial’ [European Neuropsychopharmacology 53 (2021) 34–46, (S0924977X21003746), (10.1016/j.euroneuro.2021.07.092)]. European Neuropsychopharmacology. 2022 Nov;64:61-62. doi: 10.1016/j.euroneuro.2022.09.005

Corrigendum to ‘No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial’ [European Neuropsychopharmacology 53 (2021) 34–46, (S0924977X21003746), (10.1016/j.euroneuro.2021.07.092)]

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this